Key Points
- Insider sale: Director Jula Inrig sold 20,000 shares at an average $45.00 (total $900,000) under a Rule 10b5‑1 plan to cover tax withholding, reducing her stake by 15.21% to 111,473 shares (≈$5.02M).
- Broader insider selling: Multiple executives — including the CEO — have recently sold shares (many via pre‑arranged plans), a volume of transactions that could create short‑term selling pressure or investor concern.
- Fundamentals and financing: Travere reported an EPS beat (Q1 EPS $0.05 vs. -$0.24) with revenue up 55.6% YoY, prompting several analyst price‑target upgrades, while the company priced an upsized $475M convertible senior notes offering (potential liquidity boost but dilution risk if converted).
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher Cline sold 310 shares of the business's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $13,624.50. Following the completion of the sale, the chief financial officer directly owned 118,658 shares in the company, valued at $5,215,019.10. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Travere Therapeutics Trading Down 0.2%
TVTX opened at $44.70 on Thursday. The stock has a market capitalization of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61. The firm's fifty day simple moving average is $32.59 and its 200 day simple moving average is $32.83. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to analysts' expectations of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm's revenue was up 55.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.47) EPS. As a group, research analysts anticipate that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.
Key Stories Impacting Travere Therapeutics
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: TD Cowen raised its price target to $60 and keeps a "buy" rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
- Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an "overweight" rating — another bullish analyst signal adding demand. Article Title
- Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year‑over‑year, providing fundamental support for the analyst upgrades and investor optimism. No link
- Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
- Neutral Sentiment: HC Wainwright slightly trimmed long‑term EPS forecasts (FY2027–FY2030) but maintains a "Buy" rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
- Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
- Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre‑arranged Rule 10b5‑1 plans and to cover tax withholding on awards, the volume (notably the CEO's 22,500‑share sale) can create short‑term selling pressure or investor concern. Example SEC filing: CEO Form 4
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on TVTX shares. Piper Sandler raised shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price objective on the stock in a research report on Tuesday, April 14th. Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a "buy" rating in a research report on Tuesday, April 14th. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $47.00 to $57.00 and gave the company a "buy" rating in a research report on Tuesday. Citigroup boosted their price target on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Wells Fargo & Company boosted their price target on shares of Travere Therapeutics from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Travere Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $47.83.
View Our Latest Report on Travere Therapeutics
Institutional Investors Weigh In On Travere Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the 2nd quarter worth about $33,000. Fifth Third Bancorp bought a new stake in Travere Therapeutics during the 1st quarter worth about $35,000. First Horizon Corp bought a new stake in Travere Therapeutics during the 3rd quarter worth about $36,000. State of Wyoming bought a new stake in shares of Travere Therapeutics in the 4th quarter valued at about $37,000. Finally, Torren Management LLC bought a new stake in shares of Travere Therapeutics in the 4th quarter valued at about $38,000.
About Travere Therapeutics
(
Get Free Report)
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
